Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma

Andrea Tannapfel(Leipzig University), Christian Wittekind, Kerstin Krause(University Hospital Leipzig), M. Wasner, Alexander Katalinic(German Cancer Research Center), Johann Hauss, Kurt Engeland(University Hospital Leipzig), Joachim Mössner, Felix Geißler
JNCI Journal of the National Cancer Institute
July 7, 1999
10.1093/jnci/91.13.1154
Cited by 162

Related Papers

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2015|723
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
|Cell Death and Differentiation|2017|663
Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study
|The Lancet Oncology|2021|477
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
|Annals of Oncology|2016|344